TY - JOUR
T1 - Vulvodynia: What We Know and Where We Should Be Going
AU - Havemann, Logan M.
AU - Cool, David R.
AU - Gagneux, Pascal
AU - Markey, Michael P.
AU - Yaklic, Jerome L.
AU - Maxwell, Rose
AU - Iyer, Ashvin
AU - Lindheim, Steven
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Objective The aim of the study was to review the current nomenclature and literature examining microbiome cytokine, genomic, proteomic, and glycomic molecular biomarkers in identifying markers related to the understanding of the pathophysiology and diagnosis of vulvodynia (VVD). Materials and Methods Computerized searches of MEDLINE and PubMed were conducted focused on terminology, classification, and “omics” variations of VVD. Specific MESH terms used were VVD, vestibulodynia, metagenomics, vaginal fungi, cytokines, gene, protein, inflammation, glycomic, proteomic, secretomic, and genomic from 2001 to 2016. Using combined VVD and vestibulodynia MESH terms, 7 references were identified related to vaginal fungi, 15 to cytokines, 18 to gene, 43 to protein, 38 to inflammation, and 2 to genomic. References from identified publications were manually searched and cross-referenced to identify additional relevant articles. A narrative synthesis of the articles was conducted; however, meta-analysis was not conducted because of substantial heterogeneity in the studies and limited numbers of control-matched studies. Results Varying definitions of VVD complicate a meta-analysis, and standard definitions will better allow for comparisons of studies and enhance the applicability of evidence to patient populations. Although data are still limited, genomic and molecular diagnostic testings continue to be investigated as potential tools for the diagnosis of VVD.
AB - Objective The aim of the study was to review the current nomenclature and literature examining microbiome cytokine, genomic, proteomic, and glycomic molecular biomarkers in identifying markers related to the understanding of the pathophysiology and diagnosis of vulvodynia (VVD). Materials and Methods Computerized searches of MEDLINE and PubMed were conducted focused on terminology, classification, and “omics” variations of VVD. Specific MESH terms used were VVD, vestibulodynia, metagenomics, vaginal fungi, cytokines, gene, protein, inflammation, glycomic, proteomic, secretomic, and genomic from 2001 to 2016. Using combined VVD and vestibulodynia MESH terms, 7 references were identified related to vaginal fungi, 15 to cytokines, 18 to gene, 43 to protein, 38 to inflammation, and 2 to genomic. References from identified publications were manually searched and cross-referenced to identify additional relevant articles. A narrative synthesis of the articles was conducted; however, meta-analysis was not conducted because of substantial heterogeneity in the studies and limited numbers of control-matched studies. Results Varying definitions of VVD complicate a meta-analysis, and standard definitions will better allow for comparisons of studies and enhance the applicability of evidence to patient populations. Although data are still limited, genomic and molecular diagnostic testings continue to be investigated as potential tools for the diagnosis of VVD.
UR - https://corescholar.libraries.wright.edu/obgyn/21
U2 - 10.1097/LGT.0000000000000289
DO - 10.1097/LGT.0000000000000289
M3 - Article
C2 - 27984345
VL - 21
JO - Journal of the Lower Genital Tract Disease
JF - Journal of the Lower Genital Tract Disease
ER -